These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 25422990)

  • 21. Insulin analogs versus human insulin in type 2 diabetes.
    Migdalis IN
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S102-4. PubMed ID: 21864739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine.
    Strandberg AY; Hoti FJ; Strandberg TE; Christopher S; Haukka J; Korhonen P
    PLoS One; 2016; 11(3):e0151910. PubMed ID: 27031113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia.
    Davies MJ; Derezinski T; Pedersen CB; Clauson P
    Diabetes Technol Ther; 2008 Aug; 10(4):273-7. PubMed ID: 18715200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults.
    Strandberg AY; Khanfir H; Mäkimattila S; Saukkonen T; Strandberg TE; Hoti F
    Ann Med; 2017 Jun; 49(4):357-364. PubMed ID: 28042719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Obes Metab; 2009 Apr; 11(4):372-8. PubMed ID: 19267715
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.
    Toyoda M; Kimura M; Yamamoto N; Miyauchi M; Umezono T; Suzuki D
    J Nephrol; 2012; 25(6):989-95. PubMed ID: 22307438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
    Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
    Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P; Sharplin P; Yki-Jarvinen H; Riddle MC; Haring HU
    Clin Ther; 2007 Aug; 29(8):1607-19. PubMed ID: 17919543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved glycemic control with decreased hypoglycemia prevents long-term complications in type 2 diabetes patients: long-term simulation analysis using the "diabetes mellitus model".
    Maxion-Bergemann S; Huppertz E; Jacobs LD; Müller E; Walleser S
    Int J Clin Pharmacol Ther; 2005 Jun; 43(6):271-81. PubMed ID: 15968884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.
    Rosenstock J; Schwartz SL; Clark CM; Park GD; Donley DW; Edwards MB
    Diabetes Care; 2001 Apr; 24(4):631-6. PubMed ID: 11315821
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.
    Tricco AC; Ashoor HM; Antony J; Beyene J; Veroniki AA; Isaranuwatchai W; Harrington A; Wilson C; Tsouros S; Soobiah C; Yu CH; Hutton B; Hoch JS; Hemmelgarn BR; Moher D; Majumdar SR; Straus SE
    BMJ; 2014 Oct; 349():g5459. PubMed ID: 25274009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study.
    Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
    Cardiovasc Diabetol; 2009 Jan; 8():3. PubMed ID: 19152692
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes.
    Borah BJ; Darkow T; Bouchard J; Aagren M; Forma F; Alemayehu B
    Clin Ther; 2009 Mar; 31(3):623-31. PubMed ID: 19393853
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D; Simpson R; Hylleberg B; Draeger E; Bolinder J
    Clin Ther; 2004 May; 26(5):724-36. PubMed ID: 15220016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada.
    Grima DT; Thompson MF; Sauriol L
    Pharmacoeconomics; 2007; 25(3):253-66. PubMed ID: 17335310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study.
    Gordon J; Pockett RD; Tetlow AP; McEwan P; Home PD
    Int J Clin Pract; 2010 Nov; 64(12):1609-18. PubMed ID: 20946269
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
    Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
    Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial.
    Rosenstock J; Fonseca V; Schinzel S; Dain MP; Mullins P; Riddle M
    J Diabetes Complications; 2014; 28(5):742-9. PubMed ID: 24856612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.